A potent novel small molecule GLP-1R agonist identified by rational design and CADD

Key Points

• The novel small molecule GLP-1R agonist significantly enhances insulin secretion, improving glucose metabolism.
• Key evidence includes a 45% increase in insulin release in preclinical models, showing its potential efficacy.
• CADD methods were employed to design and identify the agonist, optimizing its interaction with the target receptors.
• Highlights the importance of further validation in clinical trials to confirm efficacy and safety in human populations.